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Abstract
Metabolic reprogramming is associated with tumorigenesis. However, glucose metabolism in tumors is poorly understood.
Here, we report that glucose levels are significantly lower in bulk tumor specimens than those in normal tissues of the same
tissue origins. We show that mono-ubiquitinated histone H2B (uH2B) is a semi-quantitative histone marker for glucose. We
further show that loss of uH2B occurs specifically in cancer cells from a wide array of tumor specimens of breast, colon, lung
and additional 23 anatomic sites. In contrast, uH2B levels remain high in stromal tissues or non-cancerous cells in the tumor
specimens. Taken together, our data suggest that glucose deficiency and loss of uH2B are novel properties of cancer cells in
vivo, which may represent important regulatory mechanisms of tumorigenesis.
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Introduction
Cancer cells exhibit aberrant glucose metabolism characterized
by aerobic glycolysis, a phenomenon also known as the Warburg
effect [1,2]. This metabolic reprogramming is thought to play an
important role in supplying proliferating tumors with necessary
building blocks for biomass production [3]. Compelling evidence
also indicates that oncogenes and tumor suppressors play opposing
roles in regulating glucose metabolism [3]. Despite the importance
of glucose metabolism in tumors, it is not known whether high
glucose levels are required for cancer cells to maintain their
proliferative advantage in vivo.
Results and Discussion
To determine glucose levels in human tumors and normal
tissues, we first assayed the glucose contents in matched clinical
tumor specimens and normal tissues of the same tissue origins.
Because of the inherent variability of clinical tissue specimens [4],
we normalized the glucose levels with the total protein from the
matched specimens, an approach that has been adopted by others
[5]. Although it is difficult to estimate the total protein levels in
cancer and normal cells as a result of the tumor heterogeneity, the
total protein level in tumor interstitial fluid is comparable to that of
normal subcutaneous fluid in xenograft models [6], suggesting that
the total protein levels might be operationally useful for
normalizing the glucose amounts in inherently-variant clinical
tumor and matched normal tissue specimens. As shown in Fig. 1,
the relative amounts of glucose from frozen and unfixed human
breast, prostate and colon tumor specimens were much lower than
those of normal cells of the same tissue sites, indicating that glucose
may be deprived in the bulk tumor specimens. These results are
consistent with the observation that lower amounts of glucose are
detected in tumor veins than in tumor arteries in rats [2]. These
results are also in agreement with the fact that lower amounts of
glucose are found in tumor interstitial fluid than in normal
subcutaneous interstitial fluid in xenograft models [6]. Moreover,
these results are consistent with the finding that glucose levels,
detected by low-resolution bioluminescence assays, are drastically
increased in bulk tumor specimens that have been treated with
chemotherapy or radiation in comparison to untreated tumors in
a xenograft model for lung cancer [7].
Tumors are typically heterogeneous organs with a microenviron-
mentofvariousnon-malignantcelltypesbothwithinthetumorarea
and in their stromal environment [8]. Therefore, we reasoned that
a glucosemarker wouldbe required toidentify the cellular source of
glucose deprivation in the bulk tumor specimens. We have
previously demonstrated that glucose is the sole nutrient inducer
of mono-ubiquitination of histone H2B (uH2B) at K123 in yeast,
andatitsorthologoussiteK120inhumancells[9,10,11],indicating
that uH2B is an evolutionarily conserved chromatin marker for
glucose. To test whether uH2B could be used as a semi-quantitative
marker for glucose, we grew U87 (glioblastoma), MCF7 (breast
cancer) and HCT116 (colon cancer) in various amounts of glucose
spanning serum normal glucose levels. We then analyzed the levels
of uH2B in these cells with an antibody specific to ubiquitinated
histoneH2BatK120[12].AsshowninFig.2,exposuretoincreasing
levels of glucose resulted in a corresponding increase in levels of
uH2Bintumorcells.Incontrast,H2Blevelsremainedunchangedin
all samples. These data suggest that uH2B can be used as a semi-
quantitative histone marker for glucose in tumor cells.
WehavereportedthatuH2Bisnotdetectableinstationaryphase
yeast by Western blotting analysis [9]. Using a yeast strain (Y117)
withFLAG-H2BasthesolesourceofH2B,weincubated stationary
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Fig.2,theuH2Blevelsalsocorrelatedwiththoseofglucose,whereas
H2Bremainedunchangedinallsamples.Takentogether,thesedata
further suggest that uH2B is an evolutionarily conserved semi-
quantitative marker for glucose in yeast and tumor cells.
We noted that uH2B levels as a function of glucose concentra-
tion were not linear in the range of glucose concentrations that we
tested. Further analysis would clarify whether some of the glucose
concentrations were at or above the saturation point for some of
the cells or whether it is due to the nonlinearity of Western blotting
analysis, which was based on chemiluminescence/X-ray film
imaging. Nevertheless, our results indicate that uH2B levels
correlate semi-quantitatively with those of glucose in yeast and
tumor cells.
To determine whether the uH2B levels as a function of relative
amounts of glucose could be detected by immunohistochemistry,
we formalin-fixed and paraffin-embedded the same batches of
glucose-treated tumor cells used for the Western blotting analyses
in Fig. 2. After hybridizing the cellblock sections with antibodies
specific to either uH2B or H2B, and horseradish peroxidase-
conjugated secondary antibody, we then counterstained the cells
with Hematoxylin. At least 1000 cells were examined for each
sample. As shown in Fig. S1, uH2B levels detected by
immunohistochemistry correlated with the amounts of glucose
Figure 1. Glucose levels in tumors are lower than those of
normal tissues of the same tissue sites. Five pairs of matched
tumor and normal tissue specimens from Biochain (B) and Origene (O)
were analyzed for glucose and protein content. The amount of glucose
was normalized with the total protein concentration. Each sample was
assayed in quadruplicate.
doi:10.1371/journal.pone.0036775.g001
Figure 2. uH2B is a semi-quantitative histone marker for glucose. Stationary phase (SP) yeast (Y117) was incubated with different amounts of
glucose for 1 hr. Brain (U87), Breast (MCF7) and colon (HCT116) cancer cell lines were grown in complete media (10% FBS/DMEM) until 40–60%
confluency and subsequently incubated with DMEM containing 10% dialyzed FBS with indicated amounts of glucose for 24 hrs. The glucose (Glc)
concentrations used in the assays covered the physiological serum glucose levels (0.07–0.12%). uH2B levels in these cells corresponded to those of
glucose semi-quantitatively. Half of the glucose-treated tumor cells were also formalin-fixed and paraffin-embedded for immunohistochemical
staining of uH2B and H2B (Fig. S1). uH2B levels, detected by immunohistochemistry, were also proportional to those of glucose, further suggesting
that uH2B may be used as a chromatin marker for glucose.
doi:10.1371/journal.pone.0036775.g002
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unchanged in all samples. Taken together, these data further
demonstrate that glucose-induced uH2B may be used as a semi-
quantitative chromatin marker for examining relative amounts of
glucose in tumor specimens from cancer patients.
To identify a cellular source of glucose deprivation observed in
the bulk tumor specimens (Fig. 1), we examined glucose-induced
uH2B levels from patient biopsies or surgery specimens. As shown
in Fig. 3a, breast cancer cells showed significantly less uH2B
staining than their adjacent stromal cells. uH2B levels also
exhibited a clear demarcation between cancer cells and their
adjacent normal cells. For instance, uH2B staining was intense in
both myoepithelial and luminal epithelial cells in normal breast
duct (Duct 1, BC-D9 breast cancer specimen, Fig. 3a). However,
uH2B levels were significantly reduced in luminal epithelial cancer
cells that had undergone transformation while remained un-
changed in normal luminal epithelial cells in Duct 2. In contrast,
H2B levels were the same in both normal and cancer cells. In
another breast cancer case, uH2B levels were also lower in cancer
cells while uH2B levels remained high or unchanged in adjacent
normal tissue (BC-01, Fig. 3a). Similarly, uH2B levels were also
lower in cancer cells compared to their adjacent non-cancer cells
in 33 cases of additional 34 breast cancer specimens of different
histopathological types, grades and stages.
To determine whether impairment of glucose-induced uH2B
occurs in other types of cancer cells, we analyzed tumor specimens
from colon and lung cancer patients. As shown in Fig. 3b and 3c,
impairment of uH2B was also evident in colon and lung cancer
cells. Specifically, of 36 colon tumor specimens of various types,
grades and stages, 31 cases showed lower uH2B levels in cancer
cells compared to their stromal cells. Weak uH2B levels were also
observed in 4 tumor specimens, in which no stromal cells were
present. Moderate uH2B levels in one case were detected in both
cancer and their stromal cells.
Of 36 lung cancer specimens of various types, grades and stages,
35 cases showed lower uH2B levels in cancer cells compared to
their adjacent stromal cells. One case showed low levels of uH2B
in all cells of the specimen, in which no stromal cells were present.
Therefore, impairment of uH2B was detected in virtual all breast,
colon and lung cancer cells compared to their stromal cells in 106
out of 109 cases. Furthermore, lower uH2B levels were also
observed in cancer cells of additional 23 anatomic sites compared
to their stromal tissues (n=123 per anatomic site, data not
shown). Taken together, these results indicate that impairment of
glucose-induced uH2B is characteristic of cancer cells in vivo.
As discussed earlier, glucose is the sole nutrient inducer of uH2B
in yeast and mammalian cells [9,11]. uH2B levels correlated with
the amounts of glucose in cultured cells by both Western blotting
and immunohistochemical analyses (Fig. 2 and Fig. S1). There-
fore, lower levels of uH2B in cancer cells of the tumor specimens
may thus represent glucose deprivation in cancer cells in vivo. This
is consistent with the observation that relative glucose levels were
lower in bulk tumor specimens than those of normal cells of the
same tissue origins (Fig. 1). As discussed above, uH2B levels exhibit
a clear demarcation between cancer cells and their adjacent
normal cells (Fig. 3). In addition, loss of uH2B occurs, to a similar
extent, in all cancer cells within a cancer cell nest (Fig. 3). Taken
together, these data thus suggest that glucose deficiency is
characteristic of cancer cells in vivo.
Glucose deprivation in cancer cells may be a molecular basis for
clinical detection of tumors by positron emission tomography
(PET). PET depends on the fact that tumors exhibit higher uptake
of
18F-deoxyglucose. Since
18F-deoxyglucose uptake inversely
correlates with glucose concentrations in cultured cells [13],
PET detection of
18F-deoxyglucose uptake in tumors may reflect
glucose deprivation in cancer cells. Because glucose deficiency can
select cells with oncogenic mutations in vitro [14], glucose
deprivation of cancer cells in vivo, as demonstrated in this study,
may offer a proliferative advantage of cancer cells in patients.
We have previously reported that glucose-induced uH2B
regulates expression of metabolic genes in yeast [9]. Others have
recently shown that uH2B is also required for DNA repair in yeast
and mammalian cells [15,16,17]. Since uH2B was impaired in
virtually all cancer cells from breast, colon, lung and additional 23
Figure 3. Glucose-induced uH2B is significantly impaired in cancer cells compared to their adjacent stromal tissues. Human breast,
colon and lung tumor specimens from surgery were immunohistochemically stained for uH2B and H2B and subsequently counter-stained with
Hematoxylin. A. uH2B levels are inhibited in breast cancer cells in 36 out of 37 cases. Two representative cases are shown. Intense staining of uH2B
was observed in normal myoepithelial and luminal epithelial cells of Duct 1 of a tumor specimen from breast cancer patient BC-D9. Although it was in
the tumor specimen, Duct 1 had no cancer cells. uH2B was significantly reduced in luminal epithelial cancer cells, which was encircled with a dashed
line in Duct 2. In contrast, uH2B remained high in normal luminal epithelial cells in Duct 2. Other cancer cells in BC-D9 tumor specimen were not
separated with dashed lines for the purpose of clarity. Breast cancer cells from patient BC-01 also showed low uH2B staining, whereas adjacent
normal cells maintained high uH2B staining. B. uH2B levels are drastically reduced in colon cancer cells in 35 out of 36 cases. Two representative
cases are shown. C. uH2B levels are significantly inhibited in lung cancer cells in 35 out of 36 cases. Two representative cases are shown. The black
arrow shows a piece of cigarette tar. N denotes normal cells or stromal tissues. C denotes cancer cells. Dashed lines demarcate cancer cells from their
adjacent normal or stromal cells. Scale bar =50 m
doi:10.1371/journal.pone.0036775.g003
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m.anatomic sites that we have tested, coupling of glucose deprivation
with loss of uH2B may likely play an important role in regulating
metabolic reprogramming and DNA damage response in tumor-
igenesis.
Materials and Methods
Cell Lines, Culture Media, Chemicals and Antibodies
U87 MG human glioblastoma (grade IV) cells and MCF7
(ATCC) were maintained in high-glucose Dulbecco’s modified
Eagle’s medium (DMEM) (4.5 g/L glucose, 0.584 g/L glutamine
and 110 mg/L pyruvate, (catalog # 11995, Gibco) supplemented
with 10% fetal bovine serum (catalog # A15–351, PAA
Laboratories) and 1% penicillin/streptomycin (P/S) at 37uCi n
a humidified atmosphere of 95% air and 5% CO2. LnCap and
HCT116 (ATCC) were cultured in RPMI 1640 medium (catalog
# 11875, Gibco) supplemented with 10% FBS and 1% P/S at
37uC in a humidified atmosphere of 95% air and 5% CO2. FBS
(10 ml) was dialyzed against PBS (pH 7.4, 261 liter) at 4uC for
48 hrs. The dialyzed FBS (dFBS) was filtered through 0.22 mm
filter unit (Millipore) and stored at 4uC until use.
Glucose minus DMEM (catalog # 11966, Gibco) contained
584 mg/L L-glutamine but no glucose. Glucose minus RPMI
1640 (catalog # 22400, Gibco) contained L-glutamine but no
glucose. Mouse monoclonal antibody specific to ubiquitinated
histone H2B at K120 was from Medimabs (catalog # MM-0029-
P) [12]. Histone H2B antibody (ChIP grade) was from Abcam
(catalog # ab1790). Beta-actin antibody was from Abcam (catalog
# ab8224). Peroxidase-conjugated immuno pure goat anti-mouse
IgG (H+L) (catalog # 31430) and peroxidase-conjugated immuno
pure goat anti-rabbit IgG (H+L) (catalog # 31460) were
purchased from Pierce.
Glucose Analysis of Human Normal Tissue and Tumor
Samples
Matched human tumor and normal tissue specimens of the
same tissue origins (the samples were paired, unfixed and frozen)
were from BioChain (Breast cancer, catalog # P8235090-PP; and
colon cancer, catalog # P8235090-PP). Additional paired tumor
and normal specimens (frozen/unfixed breast, prostate and colon
tumor/normal tissues CP5656504; CP565671; CP5655651;
CP565424; CP5655718; CP565608) were from Origene. Glucose
was assayed as previously described [9]. Protein concentration was
estimated with CB-X Protein Assay Kit (catalog # 786-12X, G
Biosciences).
Analysis of Glucose-regulated uH2B in Cultured Tumor
Cells and Yeast
U87 (Glioblastoma), MCF7 (breast cancer), LnCap (prostate
cancer), and HCT116 (colon cancer) were cultured in 60 mm
dishes with high-glucose DMEM or RPMI 1640 supplemented
with 10% FBS and 1% P/S until they were 40–60% confluent.
After the media were removed, cells were rinsed twice with
phosphate buffered saline (PBS) and subsequently incubated with
glucose minus medium DMEM (catalog # 11966) or RPMI 1640
(catalog # 22400) supplemented with 10% dialyzed FBS and 1%
P/S and 0%, 0.045% or 0.450% glucose for 24, 40, or 48 hrs.
Although some cells became detached during the glucose-minus
medium incubation, virtual all of the detached cells excluded
Trypan Blue (data not shown), suggesting that they were alive.
To collect both attached and detached cells, we scraped the
attached cells in glucose minus medium with cell scrapers (catalog
# 353085, BD) and collected the cell suspension by centrifugation
at 200 g for 2 min. The cell pellets were boiled in 4 X SDS-PAGE
sample buffer at 100uC for 5 min. Protein concentration was
estimated with CB-X Protein Assay Kit (catalog #786-12X, G
Biosciences) and normalized by Western blotting. For yeast
analysis, stationary phase (SP) yeast (Y117), which contained
FLAG-tagged H2B as the sole source of H2B (submitted), was
incubated with different amounts of glucose for 1 hr and harvested
for Western blotting analysis as described [9]. The intensity of
Western blotting signals was estimated with Image J.
To correlate Western analysis with immunohistochemical
analysis, half of the harvested cells were formalin-fixed and
paraffin-embedded. Specifically, cell suspension were centrifuged
at 200 g for 2 min and washed once with PBS. Washed cells were
collected by centrifugation and re-suspended by 1:10 buffer diluted
formalin at room temperature for 24 hrs, subsequently paraffin-
embedded and immunohistochemically stained.
Immunohistochemical Analysis of Clinical Tumor
Specimens
Breast, colon and lung tumor arrays were from Pantomics
(catalog # BRC962, COC962 and LUC962). Tumor arrays from
27 anatomic sites were from BioChain (catalog # Z7020082, lot #
B412135). Mach 4 Universal HRP-Polymer Detection Kit
(Biocare Medical, LLC) were used for immunohistochemical
analyses with 200 x dilution of the antibody raised against
a synthetic branch peptide of ubiquitinated histone H2B at K120
[12] (Medimabs, catalog # MM-0029-P) or histone H2B antibody
(Abcam, catalog # ab1790). All images (406) were captured and
analyzed with an Aperio scanner (USC).
Supporting Information
Fig. S1 Tumor cells, from the same batches of the
glucose-treated cells that were used in Western blotting
analysis (Fig. 2), were formalin-fixed and paraffin-
embedded for immunohistochemical staining of uH2B
and H2B. These cells were subsequently counterstained with
Hematoxylin. At least 1000 cells were examined for each sample.
uH2B levels correlated with the amounts of glucose (Glc) of the
media for culturing glioblastoma cells (U87, A), breast cancer
(MCF7, B) and colon cancer (HTC116, C) cells. Scale bar
=50m .
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